Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF (589720) Latest Quoted at RMB 0.88, SSE Science And Technology Innovation Board Innovative Drugs Index (950161) Down 0.91%

NewTimeSpace (newtimespace.com) News, as of 10:42 on September 8, 2026, the SSE Science And Technology Innovation Board Innovative Drugs Index (950161) fell 0.91%, with the Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF (589720) last quoted at RMB 0.88.

In terms of liquidity, the Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF recorded an intraday turnover rate of 4.41% and turnover of RMB 202 million. Over a longer horizon, as of September 7, the ETF's average daily turnover over the past month stood at RMB 947 million.

In terms of scale, the Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF's AUM grew by RMB 172 million over the past week, achieving significant growth. (Source: Wind)

In terms of shares, the ETF's latest shares outstanding reached 5.240 billion units, hitting a new high over the past year. (Source: Wind)

In terms of fund flows, the Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF's latest fund net inflow was RMB 52.1357 million. Over a longer horizon, within the past 5 trading days, there were 4 days with net fund inflows, aggregating to RMB 335 million in net inflows ("fund attraction"), and an average daily net inflow of RMB 66.9963 million. (Source: Wind)

Data shows that leveraged funds continue to build positions. The ETF's margin net buy amount on the previous trading day reached RMB 7.1492 million, and its latest margin balance stood at RMB 422 million. (Source: Wind)

As of September 7, the Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF's net value had risen 6.19% over the past six months, ranking 886/4909 among index equity funds, placing it in the top 18.05%. In terms of return capability, as of September 7, 2026, since its inception, the ETF's highest single-month return was 5.48%, its longest winning streak was 2 months, its longest rally gain was 6.23%, and its average return rate in rising months was 3.73%. As of September 7, 2026, the ETF's annualized excess return over the benchmark over the past 3 months was 3.26%.

In terms of drawdown, as of September 7, 2026, the ETF's drawdown relative to the benchmark over the past six months was 0.15%, and the number of days for post-drawdown recovery was 25.

In terms of fees, the ETF's management fee rate is 0.50% and its custody fee rate is 0.10%.

In terms of tracking precision, as of September 7, 2026, the ETF's year-to-date tracking error was 0.032%.

In terms of valuation, the SSE Science And Technology Innovation Board Innovative Drugs Index tracked by the Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF (589720) has a latest price-to-earnings ratio (PE-TTM) of only 80.18x, at the 2.94% percentile over the past year, meaning its valuation is below that of over 97.06% of the time over the past year, placing it at a historic low.

The Guotai SSE Science And Technology Innovation Board Innovative Drugs ETF (589720) closely tracks the SSE Science And Technology Innovation Board Innovative Drugs Index. The SSE Science And Technology Innovation Board Innovative Drugs Index selects the securities of no more than 30 listed companies in the innovative drugs field from the Science and Technology Innovation Board as its samples, so as to reflect the overall performance of the securities of innovative-drugs listed companies on the Science and Technology Innovation Board.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.